NeuroDerm has completed 3 Phase II studies that have established a robust platform of evidence supporting the safety, tolerability, and preliminary efficacy of ND0612 in people with Parkinson’s disease experiencing motor fluctuations.
We use essential cookies to make our website work. We would also like to set analytics cookies that help us make improvements by
measuring how our visitor use the website. These will be set only if you accept them. For further details on the cookies we use read our
Cookie Policy
To accept all cookies choose the “Accept All” button, otherwise make your selection for analytics cookies by clicking on the “Settings” bottom